Abstract
Provided herein are novel azaindazole derivatives as HCN2 modulators, pharmaceutical compositions, use of such compounds in treating central nervous system (CNS) and psychiatric disorders, namely, schizophrenia, autism and mood disorders, and processes for preparing such compounds.